


Summary
The regulation of similar biotherapeutic products varies widely among the different Latin American countries. While some of them are yet to introduce their own regulation, others — like Colombia, Brazil and Mexico — have opened ways to cheaper, complex and safe biological treatment for patients. However, many things need improving and a lot of experience is still necessary to develop a mature LATAM Biosimilars Market.
Biosimilars Latam – Colombia 2020 Forum is a unique and effective meeting point to share the information and experience Latin America’s Pharmaceutical Industry needs to develop a dynamic and thriving biosimilars market.
Join us in Colombia and trigger a quantum leap in Latin American Healthcare!
Who will
you meet?
More than:
Participants
Companies
HCPs
Patients
Academy
Investors
Institutions
Associations
Service Providers
Government Agencies
Industry Executives from Latam
- Biosimilars
- Biobetters
- Biotechnology
- Biotherapeutics
- Analytical science
- Regulatory compliance
- Quality Control
- Clinical immunology
- Scientific Affairs
- Pharmacovigilance
- Research
- Regulatory
- Business Development
- Marketing
Speakers
Vladimir Camacho Cuineme
Verseds, Colombia
Chief Executive Officer
Susana Zavala
DIGEMID, Peru
Biologic Executive
Cristian Novoa
Aurofarma, Colombia
Scientific Director and Regulatory Affairs
Latam Biosimilars’s Insight. Panel Industry Leaders
Edgar Mauricio Rubio
Indukern, Colombia
Pharmaceutical & Animal Health Division Manager
Eduardo Cioppi
mAbxience, Argentina
Regional Director – Latin America
Jaime Uribe
PROBIOMED, Mexico
CEO
Perception on Biosimilars from Local Patients and HCPs. Panel
Pharmacovigilance in Latam
Current Technology used in Latam for Biosimilars Development. Panel
International Standard for the Evaluation and Approval of Biologics/Biosimilars. Panel
What the Future of Biosimilars in Colombia is? Panel
Full programme in the PDF Agenda

Sponsors
Photo Gallery from Previous Events
